BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 9, 2019
View Archived Issues
Discovery of novel HCV inhibitor L-0909
Read More
GlaxoSmithKline presents the discovery of GSK-778
Read More
Epigenetic inactivation of CELF2 associated with shorter overall survival in breast cancer
Read More
Phase II results support further study of AAV2-REP1 gene therapy in patients with choroideremia
Read More
Novel type of galactosemia caused by GALM gene mutations revealed
Read More
Study partially rehabilitates telomerase in cancer
Read More
Rock-paper-synthetic biology
Read More
Genentech describes lead small-molecule IRAK-4 inhibitors
Read More
Asthma symptoms have distinct origins, common target
Read More
PRC2 inhibitors patented by Shanghai Institute of Materia Medica, Suzhou Suplead Life Sciences
Read More
Bristol-Myers Squibb discovers STING agonists
Read More
FDA approves Ofev for interstitial lung disease associated with scleroderma
Read More
Phase I results of inhaled 5-azacytidine for the treatment of advanced non-small cell lung cancer
Read More
Enanta Pharmaceuticals discloses new farnesoid X receptor agonists
Read More
New PD-1/PD-L1 interaction inhibitors described by Gilead Sciences
Read More
AstraZeneca presents arginase-1 and arginase-2 inhibitors
Read More
Boehringer Ingelheim, Hydra Biosciences patent TRPC6 antagonists
Read More
Vicore completes phase I study of angiotensin II type 2 receptor agonist C-21
Read More
AstraZeneca reports phase III data on Imfinzi in previously untreated extensive-stage SCLC
Read More
Bristol-Myers Squibb designs RORgammaT inverse agonists showing biologic-like efficacy
Read More
Theravance reports first-in-human data on TD-8236 for inflammatory lung disease
Read More
Acadia's phase III study of pimavanserin in dementia-related psychosis meets primary endpoint
Read More
Passage Bio licenses gene therapy program for CMT2A from Penn
Read More